The effect of moderate sedation on exocrine pancreas function in normal healthy subjects: a prospective, randomized, cross-over trial using the synthetic porcine secretin stimulated Endoscopic Pancreatic Function Test (ePFT)

What Was Tested

Researchers studied Secretin in this randomized controlled trial publication.

To study the effect of moderate sedation on the exocrine pancreas gland in a prospective, randomized trial.

Why It Was Studied

The researchers have developed a purely endoscopic collection method for the assessment of pancreatic secretory function (ePFT).

The pancreatic secretory effects of sedation medications utilized during endoscopic procedures are not completely known.

Who Took Part

By PubMed's age tags, the people studied were adults, both men and women.

Healthy volunteers were randomized by computers to one of two treatments (A-no sedation, B-sedation) in period 1 and crossed-over to the other treatment in period 2 with a minimal washout interval of 7 days.

Duodenal fluid samples were aspirated via the endoscope every 5 min for 1 h and sent on ice to their hospital laboratory for the measurement of pancreatic secretory electrolyte concentrations by autoanalyzer.

How the Study Was Run

In design terms this was a randomized and crossover study.

Random assignment meant chance, not the researchers, decided who got Secretin and who got the comparison, which limits bias.

In the crossover set-up each of the participants took both Secretin and the comparison in turn, acting as their own control.

What Was Measured

The researchers have developed a purely endoscopic collection method for the assessment of pancreatic secretory function (ePFT).

Topics PubMed links to this paper include Bicarbonates, Chlorides, Procedural Sedation, Duodenoscopy, Duodenum, Gastrointestinal Agents and Hypnotics and Sedatives.

What This Means in Plain Language

The paper is a randomized and crossover study of Secretin.

Its findings take up roughly 13 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2005 (The American journal of gastroenterology), a journal based in United States.

More context: the Secretin compound page, all human trials.